Modern approaches to phytotherapy in uric acid nephrolithiasis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses pathogenetic and clinical aspects of phytotherapy in patients with urolithiasis. Phytotherapy plays an important role in the treatment and metaphylaxis of uric acid nephrolithiasis. This is attributed to its efficacy and safety, including during long-term use. The article examines currently available herbal formulations with proven clinical efficacy. Herbal formulations used in patients with uric acid nephrolithiasis typically include components such as extracts of Java tea leaves (Orthosiphon stamineus), Alpinia officinarum, field horsetail, and the roots and rhizomes of Levisticum officinale. These plants are well known for their beneficial properties and have long been used in traditional medicine. The active ingredients of these herbal formulations, such as saponins, flavonoids, terpenes, fatty acids, phenolic glycosides, caffeic acid metabolites (rosmarinic and lithospermic acids), tannins, and vitamins (notably, ascorbic acid is present in all the products mentioned), have a significant impact on their therapeutic effect. The herbal formulations exhibit diuretic, anti-inflammatory, antibacterial, and antispasmodic properties. The development of new, effective herbal formulations for the treatment of uric acid nephrolithiasis, as well as the study of their therapeutic mechanisms, remain highly relevant in modern urology.

Full Text

Restricted Access

About the authors

Alexander I. Neymark

Altai State Medical University

Email: neimark.a@mail.ru
ORCID iD: 0000-0002-5741-6408
SPIN-code: 4528-7765

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Barnaul

Sergei S. Belokurov

Altai State Medical University

Author for correspondence.
Email: ser.j.b.777@mail.ru
ORCID iD: 0000-0002-9425-2668
SPIN-code: 2746-7593

Cand. Sci. (Pharmacy)

Russian Federation, Barnaul

Boris A. Neymark

Altai State Medical University

Email: neimark.b@mail.ru
ORCID iD: 0000-0001-8009-3777
SPIN-code: 7886-8442

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Barnaul

Nikolay A. Nozdrachev

Altai State Medical University

Email: nozdrachevuro@mail.ru
ORCID iD: 0000-0003-3937-7270
SPIN-code: 4800-8255

MD, Cand. Sci. (Medicine)

Russian Federation, Barnaul

Artem S. Kalnitsky

Altai State Medical University

Email: artem_kalnitsky@mail.ru
ORCID iD: 0000-0003-3500-3052
SPIN-code: 3874-6429

Cand. Sci. (Biology)

Russian Federation, Barnaul

Yulia S. Kovaleva

Altai Medical State University

Email: julia_jsk@mail.ru
ORCID iD: 0000-0002-4401-3722
SPIN-code: 4557-2065

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Barnaul

Elvira V. Maslova

Altai State Medical University

Email: elviravalerevna0922@mail.ru
ORCID iD: 0009-0003-4218-360X
Russian Federation, Barnaul

References

  1. Sorokin I, Mamoulakis C, Miyazawa K, et al. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320. doi: 10.1007/s00345-017-2008-6
  2. Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: A systemic metabolic disorder. Clin Rev Bone Miner Metab. 2011;9(3–4):207–217. doi: 10.1007/s12018-011-9106-6
  3. Polienko AK, Sevostyanova OA, Moseev VA. Some causes of urolithiasis occurrence in the world. Urologiia. 2006;(1):74–78. EDN: HVVEOH
  4. Kaprin AD, Apolikhin OI, Sivkov AV, et al. The incidence of urolithiasis in the Russian Federation from 2005 to 2020. Experimental and Clinical Urology. 2022;15(2)10–17. doi: 10.29188/2222-8543-2022-15-2-10-17 EDN: EATILC
  5. Urate urolithiasis: pathogenesis and possibilities of conservative therapy. Urologiia. 2018;(5):146–152. doi: 10.18565/urology.2018.5.146-152 EDN: YTBVZZ
  6. Kustov AV, Strelnikov AI, Lyalyakina EV, et al. Urinary tract stones: classification, structure, analysis. From chemistry towards technology step-by-step. 2021;2(1):8–23. (In Russ.) doi: 10.52957/27821900_2021_01_8 EDN: UUQATZ
  7. Perepanova TS. Review of the efficacy and safety of Canephron®N in the treatment and prevention of urinary tract infections in different groups of patients. Experimental and Clinical Urology. 2024;17(2):122–130. doi: 10.29188/2222-8543-2024-17-2-122-130 EDN: OYTUOU
  8. Kanana AY. Conservative therapy of urate nephrolithiasis. Bulletin of emergency and reconstructive surgery. 2019;4(2):60–62. EDN: ZSUXOM
  9. Arbuliev MG, Arbuliev KM, Osmanov GM. To the treatment of purulent pyelonephritis. Urology and nephrology. 1997;(6):14–17. (In Russ.) EDN: KTUXXM
  10. Kalniczkij AS. Theoretical and methodological problems of studying the pharmacological correction of urate-oxalate nephrolithiasis with the peptide antioxidant carnosine. Intercultural Communication in Education and Medicine. 2021;(2):193–199. (In Russ.) EDN: XDHHDM
  11. Avdoshin VP, Andryukhin MI, Israfilov MN, et al. Treatment and metaphylaxis of urate and mixed urolithiasis. Urologiia. 2012;(3):7–10. EDN: PFIGZF
  12. Saenko VS, Gazimiev MA, Pesegov SV. The place of mineral water in the metaphylaxis of urolithiasis. Urologiia. 2016;(2-S2):87–94. EDN: VXCKYT
  13. Ivashhenko VV, Chernyshev IV, Kalabekov AA, et al. Modern aspects of prevention and metaphylaxis of urolithiasis. Systems approach. Surgical Practice. 2017;(4):31–38. EDN: YVWZDU
  14. Ermolenko TI. The perspectives of use by phytodrugs in the treatment of urolithiasis. Belgorod State University Scientific Bulletin. Medicine. Pharmacy series. 2014;(18):205–211. (In Russ.) EDN: SYOZGR
  15. Fursa NS, Buzuk GN, Talanov AA, et al. Non-officinal species of ericaceae family as perspective akvaretics and uroantiseptics. Pharmacy Bulletin. 2016;(3):59–66. EDN: WZQVMD
  16. Dzeranov NK, Konstantinova OV, Nikonova LM, et al. The use of Urisan for the treatment of patients with urolithiasis and chronic pyelonephritis. Saratov journal of medical scientific research. 2011;7(S2):s155. (In Russ.) EDN: OKJHIB.
  17. Blyumberg BI, Osnovin OV, Fomkin RN. Phytotherapy of urate nephrolithyasis. Clinical Nephrology. 2013;(1):71–72. EDN: PXPVEB
  18. Ilyina AE, Barskova VG. Value of the phytodrugs Prolit and Urisan in the treatment of gouty patients. Modern Rheumatology Journal. 2010;4(3):39–42. doi: 10.14412/1996-7012-2010-618 EDN: MUSPGX
  19. Gorilovsky LM, Dobrokhotov MM. Biological supplement “Prolit” in complex nephrolithiasis prevention and treatment. Clinical Gerontology. 2006;12(5):57–60. EDN: JUUJSN
  20. Shaplygin LV, Monakov CzM. Canephron®N in the treatment and prevention of urolithiasis. Ural Medical Journal. 2006;(8):42–44. (In Russ.) EDN: KVPKTJ
  21. Pochernikov DG. Experience overview of the drug Canephron®N of use in urological practice from the position of evidence-based medicine. Effective Pharmacotherapy. 2021;17(25):26–31. doi: 10.33978/2307-3586-2021-17-25-26-30 EDN: YHNNAK
  22. Grigoryan ZG, Lokshin KL. Use of the drug Canephron®N in urological practice. RMJ. 2013;21(18):924–929. (In Russ.) EDN: QZUTIV
  23. Alyayev YuG, Rudenko VI, Sayenko VS, et al. Herbal preparation Canephron®N in the treatment of patients with urolithiasis. Urologiia. 2012;(6):22–25. EDN: PIVKBT
  24. Saenko VS, Kapsargin FP, Pesegov SV, Troyakov VM. Experience in using phytolysin in the integrated management of urinary tract infections and methapylactics of nephrolithiasis. Urologiia. 2017;(3):16–21. doi: 10.18565/urol.2017.3.16-21 EDN: ZAGTSV
  25. Alyaev YuG, Rudenko VI, Perekalina AN, et al. Plant-derived terpenes in treating patients with urolithiasis. Urologiia. 2016;(2-S2):103–110. EDN: VXCKZN

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 89281 от 21.04.2025.